Hosted on MSN1mon
PDS Biotech set for Phase 3 trial in HPV-positive cancer treatment
PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
We are thrilled to share that the first trial site has been initiated and activation of additional clinical sites continues,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS ...
Business Insider11d
PDS Biotechnology initiates VERSATILE-003 Phase 3 trial of Versamune HPV
PDS Biotechnology (PDSB) announced the initiation of the VERSATILE-003 Phase 3 clinical trial. The trial is now open to patient enrollment. VERSATILE-003 is a global, multi-center, randomized ...
Nasdaq10d
PDS Biotechnology Corporation Initiates VERSATILE-003 Phase 3 Clinical Trial for HPV16-Positive Head and Neck Cancer
PDS Biotech launches VERSATILE-003 Phase 3 trial to evaluate Versamune® HPV with pembrolizumab for treating HPV16-positive head and neck cancer. PDS Biotechnology Corporation has announced the ...